c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights

References

• Sheikh E, Tran T, Vranic S, Levy A, Bonfil RD. Role and significance of c-KIT receptor tyrosine kinase in cancer: a review. Bosn J Basic Med Sci. 2022;22(5):683–698. doi:10.17305/bjbms.2021.7399
   PubMed Web of Science ®Google Scholar
• Waskow C, Paul S, Haller C, Gassmann M, Rodewald HR. Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. Immunity. 2002;17(3):277–288. doi:10.1016/s1074-7613(02)00386-2
   PubMed Web of Science ®Google Scholar
• Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood. 2002;100(2):661–665. doi:10.1182/blood-2002-01-0203
   PubMed Web of Science ®Google Scholar
• Li E, Hristova K. Receptor tyrosine kinase transmembrane domains: function, dimer structure and dimerization energetics. Cell Adh Migr. 2010;4(2):249–254. doi:10.4161/cam.4.2.10725
   PubMed Web of Science ®Google Scholar
• Lennartsson J, Ronnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92(4):1619–1649. doi:10.1152/physrev.00046.2011
   PubMed Web of Science ®Google Scholar
• Chan PM, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol. 2003;23(9):3067–3078. doi:10.1128/mcb.23.9.3067-3078.2003
   PubMed Web of Science ®Google Scholar
• Gilreath JA, Tchertanov L, Deininger MW. Novel approaches to treating advanced systemic mastocytosis. Clin Pharmacol. 2019;11:77–92. doi:10.2147/CPAA.S206615
   PubMed Web of Science ®Google Scholar
• Liang J, Wu YL, Chen BJ, Zhang W, Tanaka Y, Sugiyama H. The C-kit receptor-mediated signal transduction and tumor-related diseases. Int J Biol Sci. 2013;9(5):435–443. doi:10.7150/ijbs.6087
   PubMed Web of Science ®Google Scholar
• Yasuda A, Sawai H, Takahashi H, et al. Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway. Dig Dis Sci. 2007;52(9):2292–2300. doi:10.1007/s10620-007-9759-7
   PubMed Web of Science ®Google Scholar
• Feng Z-C, Riopel M, Popell A, Wang R. A survival Kit for pancreatic beta cells: stem cell factor and c-Kit receptor tyrosine kinase. Diabetologia. 2015;58(4):654–665. doi:10.1007/s00125-015-3504-0
   PubMed Web of Science ®Google Scholar
• Chaix A, Lopez S, Voisset E, Gros L, Dubreuil P, De Sepulveda P. Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells. J Biol Chem. 2011;286(8):5956–5966. doi:10.1074/jbc.m110.182642
   PubMed Web of Science ®Google Scholar
• Levy DE, Darnell JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651–662. doi:10.1038/nrm909
   PubMed Web of Science ®Google Scholar
• Hendriks RW. Drug discovery: new Btk inhibitor holds promise. Nat Chem Biol. 2011;7(1):4–5. doi:10.1038/nchembio.502
   PubMed Web of Science ®Google Scholar
• Duensing A, Heinrich MC, Fletcher CD, Fletcher JA. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest. 2004;22(1):106–116. doi:10.1081/cnv-120027585
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340–4346. doi:10.1200/jco.2006.06.2984
   PubMed Web of Science ®Google Scholar
• Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease asso ciated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3):804–815. doi:10.1038/jid.2009.281
   PubMed Web of Science ®Google Scholar
• Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pedi atric acute myeloid leukemia, and identification of an internal tan dem duplication. Haematologica. 2004;89(8):920–925.
   PubMed Web of Science ®Google Scholar
• Sakuma Y, Sakurai S, Oguni S, Hironaka M, Saito K. Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci. 2003;94(6):486–491.
   PubMed Web of Science ®Google Scholar
• Hongyo T, Li T, Syaifudin M, et al. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res. 2000;60(9):2345–2347.
   PubMed Web of Science ®Google Scholar
• Bello DM, Ariyan CE, Carvajal RD. Melanoma mutagenesis and aberrant cell signaling. Cancer Control. 2013;20(4):261–281. doi:10.1177/107327481302000404
   PubMed Web of Science ®Google Scholar
• Franceschi S, Lessi F, Panebianco F, et al. Loss of c-KIT expression in thyroid cancer cells. PLoS One. 2017;12(3):e0173913. doi:10.1371/journal.pone.0173913
   PubMed Web of Science ®Google Scholar
• Simon R, Panussis S, Maurer R, et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res. 2004;10(1 Pt 1):178–183. doi:10.1158/1078-0432.ccr-0597-3
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645–652. doi:10.1056/nejmoa011573
   PubMed Web of Science ®Google Scholar
• Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021;14(1):2. doi:10.1186/s13045-020-01026-6
   PubMed Web of Science ®Google Scholar
• Pathania S, Pentikäinen OT, Singh PK. A holistic view on c-Kit in cancer: structure, signaling, pathophysiology and its inhibitors. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188631. doi:10.1016/j.bbcan.2021.188631
   PubMed Web of Science ®Google Scholar
• Shi X, Sousa LP, Mandel-Bausch EM, et al. Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition. Proc Natl Acad Sci USA. 2016;113(33):E4784–E4793. doi:10.1073/pnas.1610179113
   PubMed Web of Science ®Google Scholar
• Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020;25(20):4764. doi:10.3390/molecules25204764
   PubMed Web of Science ®Google Scholar
• Honma Y, Kurokawa Y, Sawaki A, et al. Randomized, double-blind, placebo (PL)-controlled, Phase III trial of pimitespib (Tas-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG). J Clin Oncol. 2021;39(Suppl 15):11524.
   Google Scholar
• Advani AS, Tse W, Li H, et al. A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients with Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(2):113–118. doi:10.1016/j.clml.2020.11.018
   PubMed Web of Science ®Google Scholar
• Kampa-Schittenhelm KM, Vogel W, Bonzheim I, et al. Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia. Oncotarget. 2018;9(14):11876–11882. doi:10.18632/oncotarget.24376
   PubMedGoogle Scholar
• Heo SK, Noh EK, Kim JY, et al. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. Sci Rep. 2017;7(1):15278. doi:10.1038/s41598-017-15492-5
   PubMedGoogle Scholar
• Ikebe E, Shimosaki S, Hasegawa H, et al. Tas-116 (pimitespib), a heat shock protein 90 inhibitor, shows efficacy in preclinical models of adult T-cell leukemia. Cancer Sci. 2022;113(2):684–696. doi:10.1111/cas.15204
   PubMed Web of Science ®Google Scholar
• Katagiri S, Chi S, Minami Y, et al. Mutated KIT tyrosine kinase as a novel molecular target in acute myeloid leukemia. Int J Mol Sci. 2022;23(9):4694. doi:10.3390/ijms23094694
   PubMed Web of Science ®Google Scholar
• Pham DDM, Guhan S, Tsao H. KIT and melanoma: biological insights and clinical implications. Yonsei Med J. 2020;61(7):562–571. doi:10.3349/ymj.2020.61.7.562
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Lawrence DP, Weber JS, et al. Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition. Clin Cancer Res. 2015;21(10):2289–2296. doi:10.1158/1078-0432.CCR-14-1630
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim TM, Kim YJ, et al. Phase II trial of nilotinib in patients with metastatic malignant melanoma harboring KIT gene aberration: a multicenter trial of Korean cancer study group (UN10-06). Oncologist. 2015;20(11):1312–1319. doi:10.1634/theoncologist.2015-0161
   PubMed Web of Science ®Google Scholar
• Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14(21):6821–6828. doi:10.1158/1078-0432.ccr-08-0575
   PubMed Web of Science ®Google Scholar
• Hofmann UB, Kauczok-Vetter CS, Houben R, Becker JC. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res. 2009;15(1):324–329. doi:10.1158/1078-0432.ccr-08-2243
   PubMed Web of Science ®Google Scholar
• Rager T, Eckburg A, Patel M, et al. Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies. Cancers. 2022;14(15):3779. doi:10.3390/cancers14153779
   PubMed Web of Science ®Google Scholar
• Abdou Y, Kapoor A, Hamad L, Ernstoff MS. Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: a case report. Medicine. 2019;98(44):e17769. doi:10.1097/MD.0000000000017769
   PubMed Web of Science ®Google Scholar
• Namikawa K, Yamazaki N. Targeted therapy and immunotherapy for melanoma in Japan. Curr Treat Options Oncol. 2019;20(1):7. doi:10.1007/s11864-019-0607-8
   PubMed Web of Science ®Google Scholar
• Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463–482. doi:10.1038/nrclinonc.2017.43
   PubMed Web of Science ®Google Scholar
• Delyon J, Chevret S, Jouary T, et al. STAT3 mediates nilotinib response in KIT-altered melanoma: a phase ii multicenter trial of the French skin cancer network. J Invest Dermatol. 2018;138(1):58–67. doi:10.1016/j.jid.2017.07.839
   PubMed Web of Science ®Google Scholar
• Kondi-Pafiti A, Arkadopoulos N, Gennatas C, Michalaki V, Frangou-Plegmenou M, Chatzipantelis P. Expression of c-kit in common benign and malignant breast lesions. Tumori. 2010;96(6):978–984.
   PubMed Web of Science ®Google Scholar
• Janostiak R, Vyas M, Cicek AF, Wajapeyee N, Harigopal M. Loss of c-KIT expression in breast cancer correlates with malignant transformation of breast epithelium and is mediated by KIT gene promoter DNA hypermethylation. Exp Mol Pathol. 2018;105(1):41–49. doi:10.1016/j.yexmp.2018.05.011
   PubMed Web of Science ®Google Scholar
• Crisi GM, Marconi SA, Makari-Judson G, Goulart RA. Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol. 2005;124(5):733–739. doi:10.1309/61MV-ENEK-5EJ7-JKGF
   PubMed Web of Science ®Google Scholar
• Mastropasqua MG, Maiorano E, Pruneri G, et al. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol. 2005;18(10):1277–1282. doi:10.1038/modpathol.3800423
   PubMed Web of Science ®Google Scholar
• Vranic S, Bender R, Palazzo J, Gatalica Z. A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. Hum Pathol. 2013;44(3):301–309. doi:10.1016/j.humpath.2012.01.002
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang Y, Guan B, et al. C-kit and PDGFRA gene mutations in triple negative breast cancer. Int J Clin Exp Pathol. 2014;7(7):4280–4285.
   PubMed Web of Science ®Google Scholar
• Millis SZ, Gatalica Z, Winkler J, et al. Predictive biomarker profiling of > 6000 breast cancer patients shows heterogeneity in TNBC, with treatment implications. Clin Breast Cancer. 2015;15(6):473–481.e3. doi:10.1016/j.clbc.2015.04.008
   PubMed Web of Science ®Google Scholar
• Ahmed R, Ud Din H, Akhtar F, Afzal S, Muhammad I, Hashmi SN. Immunohistochemical expression of epidermal growth factor receptor and c-Kit in triple negative breast cancer. J Coll Physicians Surg Pak. 2016;26(7):570–572.
   PubMed Web of Science ®Google Scholar
• Gromova I, Espinoza JA, Grauslund M, et al. Functional proteomic profiling of triple-negative breast cancer. Cells. 2021;10(10):2768. doi:10.3390/cells10102768
   PubMed Web of Science ®Google Scholar
• López-Mejía JA, Tallabs-Utrilla LF, Salazar-Sojo P, Mantilla-Ollarves JC, Sánchez-Carballido MA, Rocha-Zavaleta L. c-Kit induces migration of triple-negative breast cancer cells and is a promising target for tyrosine kinase inhibitor treatment. Int J Mol Sci. 2022;23(15):8702. doi:10.3390/ijms23158702
   PubMed Web of Science ®Google Scholar
• Voigtlaender M, Schneider-Merck T, Trepel M. Lapatinib. Recent Results Cancer Res. 2018;211:19–44. doi:10.1007/978-3-319-91442-8_2
   PubMedGoogle Scholar
• Ma J, Liu X, Chen H, et al. c-KIT-ERK1/2 signaling activated ELK1 and upregulated carcinoembryonic antigen expression to promote colorectal cancer progression. Cancer Sci. 2021;112(2):655–667. doi:10.1111/cas.14750
   PubMed Web of Science ®Google Scholar
• Ding L, Yang Y, Lu Q, et al. Bufalin inhibits tumorigenesis, stemness, and epithelial-mesenchymal transition in colorectal cancer through a C-Kit/Slug Signaling axis. Int J Mol Sci. 2022;23(21):13354. doi:10.3390/ijms232113354
   PubMed Web of Science ®Google Scholar
• Küçükköse E, Peters NA, Ubink I, et al. KIT promotes tumor stroma formation and counteracts tumor-suppressive TGFβ signaling in colorectal cancer. Cell Death Dis. 2022;13(7):617. doi:10.1038/s41419-022-05078-z
   PubMed Web of Science ®Google Scholar
• Ubink I, Bloemendal HJ, Elias SG, et al. Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT). BMC Cancer. 2017;17(1):282. doi:10.1186/s12885-017-3264-y
   PubMedGoogle Scholar
• Peters NA, Constantinides A, Ubink I, et al. Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: a proof-of-concept study. Front Oncol. 2022;12:969855. doi:10.3389/fonc.2022.969855
   PubMed Web of Science ®Google Scholar
• Nalli M, Puxeddu M, La Regina G, Gianni S, Silvestri R. Emerging therapeutic agents for colorectal cancer. Molecules. 2021;26(24):7463. doi:10.3390/molecules26247463
   PubMed Web of Science ®Google Scholar
• Huo L, Sugimura J, Tretiakova MS, et al. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol. 2005;36(3):262–268. doi:10.1016/j.humpath.2005.01.011
   PubMed Web of Science ®Google Scholar
• Kruger S, Sotlar K, Kausch I, Horny HP. Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma. Oncology. 2005;68(2–3):269–275. doi:10.1159/000086783
   PubMed Web of Science ®Google Scholar
• Skenderi F, Ulamec M, Vranic S, et al. Cystic renal oncocytoma and tubulocystic renal cell carcinoma: morphologic and immunohistochemical comparative study. Appl Immunohistochem Mol Morphol. 2016;24(2):112–119. doi:10.1097/pai.0000000000000156
   PubMedGoogle Scholar
• Zimpfer A, Janke S, Huhns M, et al. C-kit overexpression is not associated with KIT gene muta tions in chromophobe renal cell carcinoma or renal oncocytoma. Pathol Res Pract. 2014;210(8):521–525. doi:10.1016/j.prp.2014.04.013
   PubMed Web of Science ®Google Scholar
• Norouzinia F, Abbasi F, Dindarian S, et al. Immunohistochemical study of C-kit expression in subtypes of renal cell carcinoma. Turk J Urol. 2018;44(1):31–35. doi:10.5152/tud.2018.91455
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124. doi:10.1056/nejmoa065044
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722–731. doi:10.1056/nejmoa1303989
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcino ma. N Engl J Med. 2017;376:354–366.
   PubMed Web of Science ®Google Scholar
• Medina López RA, Rivero Belenchon I, Mazuecos-Quirós J, Congregado-Ruíz CB, Couñago F. Update on the treatment of metastatic renal cell carcinoma. World J Clin Oncol. 2022;13(1):1–8. doi:10.5306/wjco.v13.i1.1
   PubMed Web of Science ®Google Scholar
• De Beauchene IC, Allain A, Panel N, et al. Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity. PLoS Comput Biol. 2014;10(7):e1003749.
   PubMed Web of Science ®Google Scholar
• Naumann N, Lubke J, Baumann S, et al. Adverse prognostic impact of the KIT D816V transcriptional activity in advanced systemic mastocytosis. Int J Mol Sci. 2021;22(5):2562.
   PubMed Web of Science ®Google Scholar
• Arock M, Sotlar K, Akin C, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29(6):1223–1232. doi:10.1038/leu.2015.24
   PubMed Web of Science ®Google Scholar
• Lin ZH, Han EM, Lee ES, et al. A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas. Mod Pathol. 2004;17(6):611–616. doi:10.1038/modpathol.3800108
   PubMed Web of Science ®Google Scholar
• Papayannidis C, Federico V, Fianchi L, et al. Treatment of advanced systemic mastocytosis with midostaurin: practical guidance for optimal therapy and management. Mediterr J Hematol Infect Dis. 2022;14(1):e2022073. doi:10.4084/MJHID.2022.073
   PubMedGoogle Scholar
• van Anrooij B, Oude Elberink JNG, Span LFR, et al. Midostaurin in patients with indolent systemic mastocytosis: an open-label Phase 2 trial. J Allergy Clin Immunol. 2018;142(3):1006–1008.e7. doi:10.1016/j.jaci.2018.06.003
   PubMed Web of Science ®Google Scholar
• Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019;35(5):738–751.e9. doi:10.1016/j.ccell.2019.04.006
   PubMed Web of Science ®Google Scholar
• Gao YP, Jiang JY, Liu Q. Expression and mutation of c-Kit in intracranial germ cell tumors: a single-centre retrospective study of 30 cases in China. Oncol Lett. 2016;11(5):2971–2976. doi:10.3892/ol.2016.4373
   PubMed Web of Science ®Google Scholar
• Broecker-Preuss M, Sheu SY, Worm K, et al. Expression and mutation analysis of the tyrosine kinase c-kit in poorly differentiated and anaplastic thyroid carcinoma. Horm Metab Res. 2008;40(10):685–691. doi:10.1055/s-2008-1080895
   PubMed Web of Science ®Google Scholar
• Murakawa T, Tsuda H, Tanimoto T, Tanabe T, Kitahara S, Matsubara O. Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach. Pathol Int. 2005;55(12):757–765. doi:10.1111/j.1440-1827.2005.01902.x
   PubMed Web of Science ®Google Scholar
• Tanaka T, Umeki K, Yamamoto I, et al. c-Kit proto-oncogene is more likely to lose expression in differentiated thyroid carcinoma than three thyroid-specific genes: thyroid peroxidase, thyroglobulin, and thyroid stimulating hormone receptor. Endocr J. 1995;42(5):723–728. doi:10.1507/endocrj.42.723
   PubMed Web of Science ®Google Scholar
• Tomei S, Mazzanti C, Marchetti I, et al. c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules. J Transl Med. 2012;10:7. doi:10.1186/1479-5876-10-7
   PubMed Web of Science ®Google Scholar
• Makhlouf AM, Chitikova Z, Pusztaszeri M, et al. Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma. Oncotarget. 2016;7(29):45776–45788. doi:10.18632/oncotarget.10166
   PubMedGoogle Scholar
• Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359(1):31–42. doi:10.1056/NEJMoa075853
   PubMed Web of Science ®Google Scholar
• Lorusso L, Pieruzzi L, Biagini A, et al. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. Onco Targets Ther. 2016;9:6467–6477. doi:10.2147/OTT.S84625
   PubMed Web of Science ®Google Scholar
• Takahashi S, Kiyota N, Yamazaki T, et al. A phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 2019;15:717–726.
   PubMed Web of Science ®Google Scholar
• Ito Y, Onoda N, Ito KI, et al. Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carci noma and anaplastic thyroid carcinoma. Thyroid. 2017;27:1142–1148.
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Molina JR, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014;99:1687–1693.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Centanni M, Virili C, et al. Sunitinib in the treatment of thyroid cancer. Curr Med Chem. 2019;26(6):963–972. doi:10.2174/0929867324666171006165942
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Elisei R, Muller S, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017;28:2813–2819.
   PubMed Web of Science ®Google Scholar
• Li D, Chi Y, Chen X, et al. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial. Clin Cancer Res. 2021;27(13):3567–3575. doi:10.1158/1078-0432.CCR-20-2950
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.3039
   PubMed Web of Science ®Google Scholar
• Kim KH, Kim JO, Park JY, Seo MD, Park SG. Antibody-drug conjugate targeting c-Kit for the treatment of small cell lung cancer. Int J Mol Sci. 2022;23(4):2264. doi:10.3390/ijms23042264
   PubMed Web of Science ®Google Scholar
• Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152(5):1259–1269.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–710. doi:10.1126/science.1079666
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–580. doi:10.1126/science.279.5350.577
   PubMed Web of Science ®Google Scholar
• Serrano C, George S. Gastrointestinal stromal tumor: challenges and opportunities for a new decade. Clin Cancer Res. 2020;26(19):5078–5085. doi:10.1158/1078-0432.CCR-20-1706
   PubMed Web of Science ®Google Scholar
• Wang WJ, Li HT, Yu JP, et al. Identification of key genes and associated pathways in KIT/PDGFRA wild‑type gastrointestinal stromal tumors through bioinformatics analysis. Mol Med Rep. 2018;18(5):4499–4515. doi:10.3892/mmr.2018.9457
   PubMed Web of Science ®Google Scholar
• Li K, Cheng H, Li Z, et al. Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions. Oncotarget. 2017;8(36):60589–60604. doi:10.18632/oncotarget.16014
   PubMedGoogle Scholar
• Niinuma T, Suzuki H, Sugai T. Molecular characterization and pathogenesis of gastrointestinal stromal tumor. Transl Gastroenterol Hepatol. 2018;3:2.
   PubMed Web of Science ®Google Scholar
• Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004;23(22):3999–4006. doi:10.1038/sj.onc.1207525
   PubMed Web of Science ®Google Scholar
• Ran L, Sirota I, Cao Z, et al. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discov. 2015;5(3):304–315. doi:10.1158/2159-8290.CD-14-0985
   PubMed Web of Science ®Google Scholar
• Serrano C, George S, Valverde C, et al. Novel insights into the treatment of imatinib-resistant gastrointestinal stromal tumors. Target Oncol. 2017;12(3):277–288. doi:10.1007/s11523-017-0490-9
   PubMed Web of Science ®Google Scholar
• Din OS, Woll PJ. Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther Clin Risk Manag. 2008;4(1):149–162. doi:10.2147/tcrm.s1526
   PubMedGoogle Scholar
• Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344(14):1052–1056. doi:10.1056/NEJM200104053441404
   PubMed Web of Science ®Google Scholar
• von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors. J Clin Oncol. 2018;36(2):136–143. doi:10.1200/JCO.2017.74.9705
   PubMed Web of Science ®Google Scholar
• Casali PG, Zalcberg J, Le Cesne A, et al. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European organisation for research and treatment of cancer, Italian sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels. J Clin Oncol. 2017;35(15):1713–1720. doi:10.1200/JCO.2016.71.0228
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Rankin C, Blanke CD, et al. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol. 2017;3(7):944–952. doi:10.1001/jamaoncol.2016.6728
   PubMed Web of Science ®Google Scholar
• Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620–625. doi:10.1200/jco.2007.13.4403
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24(29):4764–4774. doi:10.1200/JCO.2006.06.2265
   PubMed Web of Science ®Google Scholar
• Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20(36):5054–5058. doi:10.1038/sj.onc.1204704
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352–5359. doi:10.1200/jco.2007.15.7461
   PubMed Web of Science ®Google Scholar
• Grunewald S, Klug LR, Mühlenberg T, et al. Resistance to Avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA Kinase domain. Cancer Discov. 2021;11(1):108–125. doi:10.1158/2159-8290.CD-20-0487
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang YK, et al. Efcacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302. doi:10.1016/S0140-6736(12)61857-1
   PubMed Web of Science ®Google Scholar
• Jeffers M, Kappeler C, Kuss I, et al. Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial. Gastric Cancer. 2022;25(3):598–608. doi:10.1007/s10120-021-01274-6
   PubMed Web of Science ®Google Scholar
• Serrano C, Bauer S. New tyrosine kinase inhibitors for the treatment of gastrointestinal stromal tumors. Curr Oncol Rep. 2022;24(2):151–159. doi:10.1007/s11912-021-01165-0
   PubMed Web of Science ®Google Scholar
• Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem. 2004;279(30):31655–31663. doi:10.1074/jbc.M403319200
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, Phase 1 trial. Lancet Oncol. 2020;21(7):935–946. doi:10.1016/S1470-2045(20)30269-2
   PubMed Web of Science ®Google Scholar
• Evans EK, Gardino AK, Kim JL, et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med. 2017;9(414):eaao1690. doi:10.1126/scitranslmed.aao1690
   PubMed Web of Science ®Google Scholar
• Cioccio J, Claxton D. Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases. Expert Opin Investig Drugs. 2019;28(4):337–349. doi:10.1080/13543784.2019.1584610
   PubMed Web of Science ®Google Scholar
• Fan J, Gao L, Chen J, Hu S. Influence of KIT mutations on prognosis of pediatric patients with core-binding factor acute myeloid leukemia: a systematic review and meta-analysis. Transl Pediatr. 2020;9(6):726–733. doi:10.21037/tp-20-102
   PubMed Web of Science ®Google Scholar
• Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells. 2005;23(1):16–43. doi:10.1634/stemcells.2004-0117
   PubMed Web of Science ®Google Scholar
• Allen C, Hills RK, Lamb K, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia. 2013;27(9):1891–1901. doi:10.1038/leu.2013.186
   PubMed Web of Science ®Google Scholar
• Ashman LK, Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs. 2013;22(1):103–115. doi:10.1517/13543784.2013.740010
   PubMed Web of Science ®Google Scholar
• Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475–486. doi:10.1200/JCO.2010.30.2554
   PubMed Web of Science ®Google Scholar
• Nabil R, Hassan NM, Abdellateif MS, Gawdat RM, Elshazly SS. The prognostic role of C-KIT, TET1 and TET2 gene expression in acute myeloid leukemia. Mol Biol Rep. 2023;50(1):641–653. doi:10.1007/s11033-022-08000-0
   PubMed Web of Science ®Google Scholar
• Ayatollahi H, Shajiei A, Sadeghian MH, et al. Prognostic importance of C-KIT mutations in core binding factor acute myeloid leukemia: a systematic review. Hematol Oncol Stem Cell Ther. 2017;10(1):1–7. doi:10.1016/j.hemonc.2016.08.005
   PubMedGoogle Scholar
• Krauth MT, Eder C, Alpermann T, et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia. 2014;28(7):1449–1458. doi:10.1038/leu.2014.4
   PubMed Web of Science ®Google Scholar
• Kim HJ, Ahn HK, Jung CW, et al. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Ann Hematol. 2013;92(2):163–171. doi:10.1007/s00277-012-1580-5
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Kawashima N, Atsuta Y, et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020;4(1):66–75. doi:10.1182/bloodadvances.2019000709
   PubMed Web of Science ®Google Scholar
• Padmakumar D, Chandraprabha VR, Gopinath P, et al. A concise review on the molecular genetics of acute myeloid leukemia. Leuk Res. 2021;111:106727. doi:10.1016/j.leukres.2021.106727
   PubMed Web of Science ®Google Scholar
• Carter JL, Hege K, Yang J, et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther. 2020;5(1):288. doi:10.1038/s41392-020-00361-x
   PubMed Web of Science ®Google Scholar
• Klug LR, Corless CL, Heinrich MC. Inhibition of KIT tyrosine kinase activity: two decades after the first approval. J Clin Oncol. 2021;39(15):1674–1686. doi:10.1200/JCO.20.03245
   PubMed Web of Science ®Google Scholar
• Woodford MR, Sager RA, Marris E, et al. Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. EMBO J. 2017;36(24):3650–3665. doi:10.15252/embj.201796700
   PubMed Web of Science ®Google Scholar
• Chi SG, Minami Y. Emerging targeted therapy for specific genomic abnormalities in acute myeloid leukemia. Int J Mol Sci. 2022;23(4):2362. doi:10.3390/ijms23042362
   PubMed Web of Science ®Google Scholar
• Yaman B, Akalin T, Kandiloğlu G. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma. Am J Dermatopathol. 2015;37(5):389–397. doi:10.1097/DAD.0000000000000241
   PubMed Web of Science ®Google Scholar
• Carlino MS, Haydu LE, Kakavand H, et al. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer. 2014;111(2):292–299. doi:10.1038/bjc.2014.287
   PubMed Web of Science ®Google Scholar
• Lukenda A, Dotlic S, Vukojevic N, Saric B, Vranic S, Zarkovic K. Expression and prognostic value of putative cancer stem cell markers CD117 and CD15 in choroidal and ciliary body melanoma. J Clin Pathol. 2016;69(3):234–239. doi:10.1136/jclinpath-2015-203130
   PubMed Web of Science ®Google Scholar
• Montone KT, van Belle P, Elenitsas R, Elder DE. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol. 1997;10(9):939–944.
   PubMed Web of Science ®Google Scholar
• Montor WR, Salas AROSE, Melo FHM. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. Mol Cancer. 2018;17(1):55. doi:10.1186/s12943-018-0792-2
   PubMedGoogle Scholar
• Czarnecka AM, Bartnik E, Fiedorowicz M, Rutkowski P. Targeted Therapy in Melanoma and Mechanisms of Resistance. Int J Mol Sci. 2020;21(13):4576. doi:10.3390/ijms21134576
   PubMed Web of Science ®Google Scholar
• Iderzorig T, Kellen J, Osude C, et al. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC. Biochem Biophys Res Commun. 2018;496(2):770–777. doi:10.1016/j.bbrc.2018.01.069
   PubMed Web of Science ®Google Scholar
• Funkhouser AT, Strigenz AM, Blair BB, et al. KIT mutations correlate with higher galectin levels and brain metastasis in breast and non-small cell lung cancer. Cancers. 2022;14(11):2781. doi:10.3390/cancers14112781
   PubMed Web of Science ®Google Scholar
• Vahdatinia M, Derakhshan F, Da Cruz Paula A, et al. KIT genetic alterations in breast cancer. J Clin Pathol. 2022. doi:10.1136/jcp-2022-208611
   PubMedGoogle Scholar
• Chen EC, Karl TA, Kalisky T, et al. KIT signaling promotes growth of colon xenograft tumors in mice and is up-regulated in a subset of human colon cancers. Gastroenterology. 2015;149(3):705–17.e2. doi:10.1053/j.gastro.2015.05.042
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang J, Wang X, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;513(7518):382–387. doi:10.1038/nature13438
   PubMed Web of Science ®Google Scholar
• Bellone G, Smirne C, Carbone A, et al. KIT/stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes. Int J Oncol. 2006;29(4):851–859. doi:10.3892/ijo.29.4.851
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun T, Sun H, Yang S, Li D, Zhou D. SCF/C-Kit/JNK/AP-1 signaling pathway promotes claudin-3 expression in colonic epithelium and colorectal carcinoma. Int J Mol Sci. 2017;18(4):765. doi:10.3390/ijms18040765
   PubMed Web of Science ®Google Scholar
• Li G, Yang S, Shen P, et al. SCF/c-KIT signaling promotes mucus secretion of colonic goblet cells and development of mucinous colorectal adenocarcinoma. Am J Cancer Res. 2018;8(6):1064–1073.
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Nusse Y, Kalisky T, et al. Identification of a cKit(+) colonic crypt base secretory cell that supports Lgr5(+) stem cells in mice. Gastroenterology. 2012;142(5):1195–1205.e6. doi:10.1053/j.gastro.2012.02.006
   PubMed Web of Science ®Google Scholar
• Ergün S, Altay DU, Güneş S, et al. Tr-KIT/c-KIT ratio in renal cell carcinoma. Mol Biol Rep. 2019;46(5):5287–5294. doi:10.1007/s11033-019-04985-3
   PubMed Web of Science ®Google Scholar
• Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. Esmo Open. 2020;5:e001079. doi:10.1136/esmoopen-2020-001079
   PubMed Web of Science ®Google Scholar
• Capitanio U, Fallara G, Raggi D, et al. Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence. Curr Probl Cancer. 2022;46(4):100875. doi:10.1016/j.currproblcancer.2022.100875
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. doi:10.1056/NEJMoa2035716
   PubMed Web of Science ®Google Scholar
• Pardanani A. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. Am J Hematol. 2021;96(4):508–525. doi:10.1002/ajh.26118
   PubMed Web of Science ®Google Scholar
• Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727–5736.
   PubMed Web of Science ®Google Scholar
• Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005;106(2):721–724.
   PubMed Web of Science ®Google Scholar
• Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009;4(9):e7258.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Giles FJ, et al. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol. 2015;141(11):2047–2060.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008;14(12):3906–3915.
   PubMed Web of Science ®Google Scholar
• Alvarez-Twose I, Matito A, Morgado JM, et al. Imatinib in systemic mastocytosis: a Phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget. 2016;8(40):68950–68963.
   PubMedGoogle Scholar
• Ustun C, Courville EL. Resolution of osteosclerosis after alloHCT in systemic mastocytosis. Blood. 2016;127(14):1836. doi:10.1182/blood-2016-01-690669
   PubMed Web of Science ®Google Scholar
• Oosterhuis JW, Looijenga LH. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer. 2005;5(3):210–222. doi:10.1038/nrc1568
   PubMed Web of Science ®Google Scholar
• Coffey J, Linger R, Pugh J, et al. Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosomes Cancer. 2008;47(1):34–42. doi:10.1002/gcc.20503
   PubMed Web of Science ®Google Scholar
• McIntyre A, Summersgill B, Grygalewicz B, et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res. 2005;65(18):8085–8089. doi:10.1158/0008-5472.CAN-05-0471
   PubMed Web of Science ®Google Scholar
• Nakai Y, Nonomura N, Oka D, et al. KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumors. Biochem Biophys Res Commun. 2005;337(1):289–296. doi:10.1016/j.bbrc.2005.09.042
   PubMed Web of Science ®Google Scholar
• Willmore-Payne C, Holden JA, Chadwick BE, Layfield LJ. Detection of c-kit exons 11- and 17-activating mutations in testicular seminomas by high-resolution melting amplicon analysis. Mod Pathol. 2006;19(9):1164–1169. doi:10.1038/modpathol.3800623
   PubMed Web of Science ®Google Scholar
• Przygodzki RM, Hubbs AE, Zhao FQ, O’Leary TJ. Primary mediastinal seminomas: evidence of single and multiple KIT mutations. Lab Invest. 2002;82(10):1369–1375. doi:10.1097/01.lab.0000032410.46986.7b
   PubMed Web of Science ®Google Scholar
• Sakuma Y, Sakurai S, Oguni S, Satoh M, Hironaka M, Saito K. c-kit gene mutations in intracranial germinomas. Cancer Sci. 2004;95(9):716–720. doi:10.1111/j.1349-7006.2004.tb03251.x
   PubMed Web of Science ®Google Scholar
• Hersmus R, Stoop H, van de Geijn GJ, et al. Prevalence of c-KIT mutations in gonadoblastoma and dysgerminomas of patients with disorders of sex development (DSD) and ovarian dysgerminomas. PLoS One. 2012;7(8):e43952. doi:10.1371/journal.pone.0043952
   PubMed Web of Science ®Google Scholar
• Cheng L, Roth LM, Zhang S, et al. KIT gene mutation and amplification in dysgerminoma of the ovary. Cancer. 2011;117(10):2096–2103. doi:10.1002/cncr.25794
   PubMed Web of Science ®Google Scholar
• Sever M, Jones TD, Roth LM, et al. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. Mod Pathol. 2005;18(11):1411–1416.
   PubMed Web of Science ®Google Scholar
• Stemberger-Papić S, Vrdoljak-Mozetic D, Ostojić DV, et al. Expression of CD133 and CD117 in 64 serous ovarian cancer cases. Coll Antropol. 2015;39(3):745–753.
   PubMedGoogle Scholar
• Natali PG, Berlingieri MT, Nicotra MR, et al. Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res. 1995;55(8):1787–1791.
   PubMed Web of Science ®Google Scholar
• Pusztaszeri MP, Sadow PM, Faquin WC. CD117: a novel ancillary marker for papillary thyroid carcinoma in fine-needle aspiration biopsies. Cancer Cytopathol. 2014;122(8):596–603. doi:10.1002/cncy.21437
   PubMed Web of Science ®Google Scholar
• Hida T, Ueda R, Sekido Y, et al. Ectopic expression of c-kit in small-cell lung cancer. Int J Cancer Suppl. 1994;8:108–109. doi:10.1002/ijc.2910570723
   PubMedGoogle Scholar
• Yokouchi H, Nishihara H, Harada T, et al. Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-betaRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker. Oncotarget. 2017;8(24):39711–39726. doi:10.18632/oncotarget.14410
   PubMedGoogle Scholar
• Lu HY, Zhang G, Cheng QY, et al. Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer. Oncol Lett. 2012;4(1):89–93. doi:10.3892/ol.2012.679
   PubMed Web of Science ®Google Scholar
• Yang H, Wang F, Deng Q, et al. Predictive and prognostic value of phosphorylated c-KIT and PDGFRA in advanced non-small cell lung cancer harboring ALK fusion. Oncol Lett. 2019;17(3):3071–3076. doi:10.3892/ol.2019.9972
   PubMed Web of Science ®Google Scholar
• Zhang L, Jiang T, Li X, et al. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer. Cancer. 2017;123(15):2927–2935. doi:10.1002/cncr.30677
   PubMed Web of Science ®Google Scholar
• Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000;19(31):3521–3528. doi:10.1038/sj.onc.120369831
   PubMed Web of Science ®Google Scholar
• Soria JC, Johnson BE, Chevalier TL. Imatinib in small cell lung cancer. Lung Cancer. 2003;41 Suppl 1:S49–S53. doi:10.1016/s0169-5002(03)00142-9
   PubMed Web of Science ®Google Scholar
• Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003;9(16 Pt 1):5880–5887.
   PubMedGoogle Scholar
• Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. doi:10.1186/s13045-018-0664-7
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang Q, Li K, et al. OA13.03 anlotinib as thirdline or further-line treatment in relapsed SCLC: a multicentre, randomized, double-blind phase 2 trial. J Thorac Oncol. 2018;13:S351–2.
   Web of Science ®Google Scholar